)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
BioLineRx (BLRX) investor relations material
BioLineRx Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary24 Nov, 2025
Executive summary
Formed a joint venture with Hemispherian to develop GLIX1, a first-in-class oral small molecule targeting glioblastoma and other cancers, with a phase I/II-A trial set to begin in Q1 2026 and leveraging complementary expertise in clinical development and small molecule discovery.
GLIX1's IND was cleared by the FDA in August, with initial phase 1 data expected in H1 2027.
Retained rights to develop metixafortide in pancreatic cancer (PDAC) and continue to support its development through the CheMo4METPANC phase II-B trial in collaboration with Columbia University and Regeneron.
Maintains a cash runway into the first half of 2027, with $25.2 million in cash and equivalents as of September 30, 2025.
Financial highlights
Q3 2025 total revenues were $0.4 million, reflecting royalties from APHEXDA commercialization.
Research and development expenses were $1.7 million, down from $2.6 million in Q3 2024, mainly due to lower metixafortide-related costs, out-licensing, and reduced headcount.
No sales and marketing expenses in Q3 2025, compared to $5.5 million in Q3 2024, following the shutdown of U.S. commercial operations.
General and administrative expenses were $0.8 million, down from $1.4 million year-over-year.
Net loss for Q3 2025 was $1 million, compared to $5.8 million in Q3 2024.
Outlook and guidance
GLIX1 phase I/II-A trial in glioblastoma to start in Q1 2026, with phase 1 data anticipated in H1 2027 and potential periodic updates before then.
Plans to expand GLIX1 development into additional cancer indications after establishing safety and dosing.
Ongoing support for metixafortide in PDAC and sickle cell disease, with key data presentations expected at upcoming conferences and interim analysis planned at 40% PFS events.
Cash runway expected to last into the first half of 2027.
GLIX1: Criteria for next cancer indication?
Motixafortide SCD: Next development steps?
What drives APHEXDA's meaningful growth?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next BioLineRx earnings date
Q4 202531 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
BioLineRx Ltd. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapeutics for oncology and rare diseases. The company's primary product pipeline includes therapies aimed at treating multiple myeloma, sickle cell disease, pancreatic cancer, and other solid tumors. BioLineRx leverages extensive drug development expertise to advance these therapies from preclinical stages through to commercialization. The company is headquartered in Hevel Modi'in, Israel, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage